Cardiol Therapeutics Inc.
CRDL Nasdaq· Biological Products, (No Diagnostic Substances)
KIRA · Stoqly’s AI analyst, in plain words
- Cardiol Therapeutics Inc. lost $24.2M in fiscal 2025.
- Free cash flow was −$17.1M in fiscal 2025, — of revenue.
Market cap
—
P/E
—
Revenue
—
Net income
−$24.2M
Free cash flow
−$17.1M
Operating margin
—
Cardiol Therapeutics Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$24.2M
No. It lost money last year.
What Cardiol Therapeutics Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 40-F · Mar 31, 2026
- Legal name
- Cardiol Therapeutics Inc.
- CIK
- 0001702123
Cardiol Therapeutics Inc. · CRDL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.1M | — | — | — | — |
| Operating margin | −49,113.9% | — | — | — | — |
| Net income | −$25.2M | −$23.8M | −$20.8M | −$26.8M | −$24.2M |
| Net margin | −40,188.4% | — | — | — | — |
| Diluted EPS | −$0.58 | −$0.38 | −$0.33 | −$0.37 | −$0.28 |
| Cash | |||||
| Cash from operations | −$18.8M | −$20.9M | −$18.7M | −$18.3M | −$17.1M |
| Capital expenditure | $0.0M | $0.1M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$18.8M | −$21.0M | −$18.7M | −$18.3M | −$17.1M |
| FCF margin | −29,917.5% | — | — | — | — |
| Share count change | 44.8% | 44.6% | 3.1% | 11.0% | 21.5% |
| Debt and strength | |||||
| Cash and short-term investments | $66.0M | $43.9M | $26.4M | $21.3M | $15.6M |
| Shareholders' equity | $60.0M | $38.6M | $21.3M | $17.2M | $13.1M |
| Current ratio | 7.5x | 6.3x | 4.4x | 4.5x | 4.2x |
| Returns and quality | |||||
| Return on equity | −71.7% | −48.2% | −69.6% | −139.1% | −160.0% |
| Return on tangible equity | −42.3% | −62.0% | −98.5% | −155.8% | −185.2% |
| Altman Z'' | 6.4 | 0.4 | −9.5 | −18.5 | −30.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cardiol Therapeutics Inc. · CRDL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Source: SEC EDGAR XBRL filings (CIK 0001702123). Data updated October 24, 2026. Filed in CAD under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.